Workflow
Thermo Fisher Scientific(TMO)
icon
Search documents
Thermo Fisher Scientific Shares Up 3.3% After Power Inflow Signal
Benzinga· 2025-09-30 18:54
Thermo Fisher Scientific Inc (NYSE:TMO) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.At 10:36 AM EST on September 30, TMO triggered a Power Inflow signal at a price of $464.71. Prior to the alert, TMO had been stagnant during the first hour of trading, with the stock price not moving far off the opening price. At the time of the Power Inflow signal, both the insti ...
Vaxcyte Thermo Fisher ink deal for vaccine production (PCVX)
Seeking Alpha· 2025-09-30 13:03
Vaxcyte (NASDAQ:PCVX) announced a long-term agreement worth up to $1B with Thermo Fisher Scientific (NYSE:TMO) on Tuesday to support the future commercial production of its pneumonia vaccines. Under the agreement, which Vaxcyte (NASDAQ:PCVX) cited as a key component in ...
质谱新品再占四席,2025年上半年3i优秀新品提名奖公布!
仪器信息网· 2025-09-27 03:58
"3i奖-科学仪器行业优秀新品奖"评选活动,2025年上半年提名奖评审已经顺利结束。在2025年2月15日至7月15日期间,国内外仪器厂商 共申报了243台仪器新品,其中包含2024年和2025年上市的新品。 各位评审专家按照严格的评审程序,对申报的新品进行网上、网下的评议,逐一进行打分并给出评审意见。"技术评审委员会主席团"承担各个 阶段评审工作的监督、检查工作,对"提名奖"名录、年度"优秀新品奖"名录拥有最终裁决。"3i奖-科学仪器行业优秀新品奖"评审团队由300 余位业内资深专家组成,分别来自高校、研究所和企业,从事仪器研制、制造和应用相关工作,并热心仪器事业、办事公正,具有研究员、教 授等高级职称的专家所占比例超过了90%。 经专业编辑团初审、网络评审团评审、技术评审委员会主席团审核,现已确定2025年上半年"提名奖"名单。荣获2025年上半年"提名奖"的新 品共有40台,比例约为16%。 其中,质谱类共有4款新品获得"提名奖"。 "3i奖-科学仪器优秀新品奖"2025年上半年"提名奖"名单(排名不分先后) 摘要 : 经专业编辑团初审、网络评审团评审、技术评审委员会主席团审核,现已确定2025年上半年 ...
Dr. Park CDMO Selects Thermo Fisher Scientific to Equip New Viral Vector Manufacturing Facility
Businesswire· 2025-09-25 00:00
Core Insights - Dr. Park CDMO has selected Thermo Fisher Scientific to equip its new viral vector manufacturing facility, aiming to enhance large-scale production and global access to cell and gene therapies [1][4] Group 1: Company Overview - Dr. Park specializes in Adeno-associated virus-based (AAV-based) viral vector production, currently operating at a capacity of 5,000 L per batch and producing up to 40 clinical-grade batches annually [2] - The new Phase 1 facility was inaugurated on August 5, 2025, with plans to achieve cGMP certification in 2026 and to expand capacity to 10,000 L per batch in the future [2] Group 2: Technological Integration - The facility will utilize several advanced solutions from Thermo Fisher, including the HyPerforma™ 1,000 L Single-Use Bioreactor and DynaSpin™ Single-Use Centrifuge, aimed at streamlining production processes and enhancing efficiency [3] - These technologies are designed to improve process control and automation, thereby supporting rapid scale-up from clinical to commercial production while maintaining high standards of quality and regulatory compliance [3] Group 3: Strategic Collaboration - The collaboration between Dr. Park CDMO and Thermo Fisher is seen as crucial for advancing viral vector manufacturing in South Korea, reflecting the growing importance of robust manufacturing infrastructure for cell and gene therapies [4][5] - Both companies emphasize the need for collaboration to accelerate the development and delivery of therapies to patients, addressing the rising global demand for gene therapy [5]
Thermo Fisher: A Wide-Moat Leader With Multi-Year Growth Ahead
Seeking Alpha· 2025-09-24 12:37
Thermo Fisher (NYSE: TMO ) shares have been on an incredible upward trajectory during the Covid-19 pandemic. Ever since testing kits launched that helped us regaining more and more of our freedoms, the company producing themI am an investor and analyst with a strong focus on long-term compounders, high-moat businesses, and structurally growing industries. My core interest lies in identifying durable companies with economic resilience, pricing power, and capital efficiency — the kind of businesses that outpe ...
HOLX vs. TMO: Which Diagnostic Giant Is the Stronger Buy Today?
ZACKS· 2025-09-22 14:25
Core Insights - Hologic and Thermo Fisher Scientific are key players in the diagnostics market, each with distinct strengths and market focuses [1][2] Hologic Overview - Hologic specializes in molecular diagnostic assays for infectious diseases, particularly in women's health, with a market cap of $14.75 billion [1] - The company has seen strong growth in its Molecular Diagnostics segment, particularly with the BV, CV/TV assay, which has become its second-largest test globally since its launch in 2019 [3] - Hologic's Breast Health business is recovering, with expectations to return to growth by Q4 of fiscal 2025, aided by new leadership and innovations [4] - The company has a strong GYN Surgical portfolio and has expanded its fibroid treatment offerings through the acquisition of Gynesonics [5] - Hologic maintains a solid financial position with $1.88 billion in cash and short-term investments and a net leverage ratio of 0.6 [6] - The company has raised its full-year revenue guidance to $1.03-$1.04 billion and adjusted EPS to $1.09-$1.12, despite facing cost pressures from tariffs [7] Thermo Fisher Overview - Thermo Fisher, valued at $181.10 billion, offers a wide range of diagnostic products and services across various sectors, including healthcare and food safety [2] - The company is experiencing growth in its bioproduction and pharma services, supported by significant innovations and product launches [8] - Thermo Fisher's capital deployment strategy includes strategic acquisitions and shareholder returns, with recent acquisitions aimed at enhancing its bioproduction capabilities [11] - The company has projected revenues between $43.6 and $44.2 billion and adjusted EPS of $22.22-$22.84 for the full year, both raised from prior estimates [13] Performance Comparison - Over the last six months, Hologic's stock has increased by 4.2%, while Thermo Fisher's stock has decreased by 7.7% [9][16] - Hologic's shares are trading at a forward five-year P/E of 14.41X, compared to Thermo Fisher's P/E of 20.12X, indicating a more favorable valuation for Hologic [17] - Analysts project a year-over-year EPS growth of 3.7% for Hologic, while Thermo Fisher's EPS is expected to improve by 3% [19][21] Investment Outlook - Both companies exhibit strong fundamentals and financial stability, with Hologic showing resilience in its growth areas and Thermo Fisher focusing on innovation and market expansion [22]
刘小涛会见赛默飞世尔科技中国区总裁方明杰
Su Zhou Ri Bao· 2025-09-20 00:06
昨天(9月19日),苏州市委书记刘小涛会见了赛默飞世尔科技中国区总裁方明杰一行。 倪黎祥 摄 会见中,刘小涛代表市委、市政府对赛默飞给予苏州发展的支持表示感谢。他说,苏州高度重视生物医药产 业发展,汇聚了一批优质项目、创新人才、产业基金,打造了一系列创新药和医疗器械产品,推动产业呈现蓬勃 发展态势。当前,我们正积极抢抓生物医药全产业链开放创新发展机遇,打造生物医药产业发展高地。赛默飞是 行业领先企业,与苏州合作基础深厚、合作空间广阔。欢迎赛默飞继续扎根苏州、深耕苏州,导入更多先进技 术、创新产品,并加强与苏州本土企业合作,为苏州生物医药产业发展注入新活力、增添新动能。我们将积极营 造市场化、法治化、国际化一流营商环境,助力企业实现更好发展。 方明杰对苏州给予赛默飞的支持帮助表示感谢。他说,苏州是赛默飞在华投资额最大的城市之一。受益于当 地良好的营商环境,赛默飞在苏项目进展顺利,取得了丰厚回报。面向未来,我们积极看好苏州生物医药产业发 展前景,将持续扩大在苏投资布局,进一步提升本土研发和生产能力,并加强与苏州产业链供应链对接合作,助 力苏州生物医药产业创新发展。 市委常委、副市长唐晓东,苏州高新区主要负责同志参 ...
Thirty Inspiring Middle School Scientists and Engineers Shine as Finalists in the Thermo Fisher Scientific Junior Innovators Challenge
Globenewswire· 2025-09-17 16:05
Core Insights - The Thermo Fisher Scientific Junior Innovators Challenge (Thermo Fisher JIC) is a premier middle school STEM competition aimed at inspiring young scientists and innovators to address future challenges [1][2] - This year's finalists have explored significant topics such as natural resource stewardship, human health protection, artificial intelligence implications, and resilient technology design [2][4] Group 1: Competition Overview - The Thermo Fisher JIC has selected 30 finalists from a pool of 300 Junior Innovators, who will compete in Washington, D.C. from October 24-29 [1][3] - Finalists will be evaluated on their scientific research, communication, creativity, and collaboration skills during team challenges [1][3] Group 2: Participant Engagement - The competition reaches approximately 60,000 students annually through the Society's Affiliated Fair Network, with eligibility for the top 10% of local science fairs [4][5] - Finalists represent 10 states and Puerto Rico, with California and Texas leading in participation [5] Group 3: Awards and Recognition - Finalists receive a $500 cash award and compete for various awards, including the $25,000 Thermo Fisher Scientific ASCEND Award and multiple $10,000 awards for specific achievements [6][10] - Schools of the finalists are recognized with $1,000 each to support STEM activities [7] Group 4: Company Commitment - Thermo Fisher Scientific emphasizes its commitment to broadening access to STEM education through sponsorship and volunteer efforts [3][4] - The initiative reflects the importance of fostering curiosity and investing in the next generation of STEM leaders [3][4]
The New Olink Target 48 Neurodegeneration Panel May Boost TMO Stock
ZACKS· 2025-09-16 15:46
Company Overview - Thermo Fisher Scientific (TMO) launched the Olink Target 48 Neurodegeneration panel, a targeted proteomics immunoassay designed to enhance neurodegenerative disease research by measuring 41 key proteins with absolute quantification from as little as 1µL of plasma sample [1][5][8] - The new panel is part of Olink's expanding portfolio of multiplex disease panels, emphasizing the company's commitment to advancing precision medicine and neurology research [2][3] Product Details - The Target 48 Neurodegeneration panel is designed to meet the increasing demand for scalable and reproducible protein measurements in the context of rising neurodegenerative diseases such as Alzheimer's and Parkinson's [5][9] - It is compatible with the Olink Signature Q100 benchtop system, facilitating a simplified workflow and minimal maintenance, which accelerates biomarker research [6][8] Market Insights - The neurodegenerative disease diagnostics market is projected to grow from $4.70 billion in 2025 at a compound annual growth rate of 7.5% through 2030, driven by the increasing prevalence of neurodegenerative disorders and advancements in diagnostic technologies [10] Financial Performance - Thermo Fisher has a market capitalization of $181.05 billion and an earnings yield of 4.7%, significantly higher than the industry's -4.2% yield [4] - Over the past three months, TMO shares have increased by 21.6%, outperforming the industry growth of 1.9% [12]
Thermo Fisher Scientific Expands Neurodegeneration Research Capabilities with Launch of Olink® Target 48 Neurodegeneration Panel
Businesswire· 2025-09-15 20:15
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the launch of the Olink® Target 48 Neurodegeneration panel, a high-performance, targeted proteomics immunoassay panel developed to accelerate discoveries in neurodegenerative disease research. With diseases such as Alzheimer's, multiple sclerosis and Parkinson's on the rise and clinical pipelines eager for translational biomarkers, researchers face a pressing need for scalable, r. ...